Navigation Links
Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
Date:10/31/2008

Data Presented at AMP Indicates Potential New Application of Tissue of Origin Test

SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, will present three studies involving the gene expression based Pathwork(R) Tissue of Origin Test at the Association for Molecular Pathology (AMP) Annual Meeting.

In a poster entitled, "Gene Expression Microarray-Based Diagnostic Test May Identify Primary Tumor Site in Patients with Carcinoma of Unknown Primary (CUP)," Fabiola Medeiros, MD, Assistant Professor of Laboratory Medicine and Pathology at the Mayo Clinic, found that the Pathwork Tissue of Origin Test indicated a probable origin of metastatic CUP in 73 percent of the tumors tested.

CUP cases account for approximately three percent of all malignancies, representing one of the 10 most frequent cancer diagnoses. The CUP samples from the Mayo Clinic consisted of 11 fresh-frozen tumor specimens, whose origin could not be determined after full clinical and imaging workup, including immunohistochemistry. The cases where the tissue of origin was identified have treatment options that show increased survival compared to standard therapies used for the treatment of CUP.

"Identifying the tumor's origin can allow oncologists to prescribe more appropriate, targeted therapy and avoid the toxicity of less-specific chemotherapies. They may also be able to enroll these patients in new therapeutic clinical trials which otherwise would not be available without a defined tissue of origin," said David Henner, MD, PhD, Chief Medical Officer of Pathwork Diagnostics.

Since the test was validated and FDA-cleared using metastatic tumors for which the primary site was known, the purpose of this study was to examine the diagnostic performance of this test using CUP specimens. Analysis of the accuracy of these results is limited, since there is no reference diagnosis for comparison with CUP specim
'/>"/>

SOURCE Pathwork Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. AxoGen Awarded Accreditation from American Association of Tissue Banks : Decision Affirms AxoGen's Commitment to Safety and Ethicality in the Development and Distribution of AVANCE Nerve Graft for Treatment of Peripheral Nerve Injuries
3. MTF, Largest Tissue Bank, Donates Skin to Mexican Burn Victim
4. MRI Detects Soft Tissue Damage Affecting Kids Hearing
5. Drug Given 24 Hours After Stroke Helps Repair Brain Tissue
6. New Research Shows Cadaver Tissue Fails Nearly a Quarter of the Time in Young, Athletic ACL Reconstruction Patients
7. ACL Reconstruction With Cadaver Tissue Risky in Younger Patients
8. New Research Shows Cadaver Tissue Fails Nearly a Quarter of the Time in Young, Athletic ACL Reconstruction Patients
9. Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions
10. Global Med Technologies(R) Announces U.S. Release of Proven Tissue and Cellular Therapy Product
11. New therapeutic options for diabetes-related tissue injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Research and surveillance urged for at-risk patient groups , , FRIDAY, Dec. 4 (HealthDay News) -- Some childhood cancers, particularly Ewing sarcomas and central nervous system tumors, carry t
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...edical,Foundation has been awarded a three-year te...rvices as the result of a recent survey by the Ame...detailed, concerted effort our team made to ensure...tified radiologist at Sutter Regional Medical Foun...
... Researchers from EPFL and Caltech have made an i...earn to predict risk. The research, appearing in ... will shed light on why certain kinds of risk, not...eous evaluation of risk. , Planning entails maki...
...rs and sisters can be tough work, as any youngest ...ologist at the University of North Carolina at Cha...ou should reserve any underdog sympathies for the ...om, which holds that baby birds that are laid befo...
...mission tomography (PET) and computed tomography (...ve method to evaluate response to radiation therap...up treatments, a study by researchers at the Unive...ailable online. , The clinical study is the first...
...tiatives are featured, DETROIT, March 12 Physici... inside look at how groundbreaking partnerships,am...ld of Michigan are,saving lives, improving patient...ted,by hospitals, physicians and the Blues to trul...
... National Chronic Disease ...rim results show,that participants in the Diabetes... clinical and patient satisfaction indicators in t...lling diabetes, the chronic,disease that affects 2...
Other Medicine News:Health News:Sutter Regional Medical Foundation Receives ACR Accreditation 2Health News:To bet or not to bet: How the brain learns to estimate risk 2Health News:Early bird doesn't always get worm, UNC researcher finds 2Health News:USC researchers find benefit for lymphoma patients in combined PET-CT scanning 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 3Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 4Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
(Date:12/3/2009)COSTA MESA, Calif., Dec. 3 TROY Group, Inc., a Worldwide Leader in Secure on-Demand Printing Solutions, announces the addition of the TROY 3015 SecureRx(TM) Printer to its line of secure prescripti
Breaking Medicine Technology:BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2Basic Facts and Statistics About Lupus 51277 1Basic Facts and Statistics About Lupus 51277 2AUL President to Senate Judiciary Committee 3A Ask Top 10 Questions to Judge Sotomayor 51274 1AUL President to Senate Judiciary Committee 3A Ask Top 10 Questions to Judge Sotomayor 51274 2REMERON 28R 29 Now Approved in Japan for the Treatment of Depression in Adult Patients 12964 1REMERON 28R 29 Now Approved in Japan for the Treatment of Depression in Adult Patients 12964 2REMERON 28R 29 Now Approved in Japan for the Treatment of Depression in Adult Patients 12964 3REMERON 28R 29 Now Approved in Japan for the Treatment of Depression in Adult Patients 12964 4REMERON 28R 29 Now Approved in Japan for the Treatment of Depression in Adult Patients 12964 5
...EULAR, BARCELONA, Spain, June 15, 2007 /PRNewswire...n League Against Rheumatism (EULAR),Annual Europea...th,ankylosing spondylitis (AS) who received REMICA...ificant improvement in spinal,mobility. In additio...ctions in spinal inflammation through two years as...
...dic: ACTI) presented,pre-clinical results for the ...gue Against Rheumatism, <a target="_blank" href=,"..., June,13-16*. , "The new pre-clinical data presen...fect on disease development in an,experimental mod...Andréasson, President & CEO Active Biot...
Other Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
Broncho-Cath® Endobronchial Tube with CPAP System
...made of silicone rubber with a wire reinforced end... of silicone rubber, Silbronco is soft and less tr...the tube will not soften like PVC tubes, which mak...lbronco is also especially useful when a tumor lif...
Portex Pedia-Trake® Pediatric Emergency Cricothyrotomy Kit
Melker Emergency Cricothyrotomy Catheter Sets
Medicine Products: